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October 9, 2012:1430–7completely occlude the ostium. The shape mismatch between
the LAA ostium and the device is clearly evidenced in the
three-dimensional transesophageal echocardiographic images,
such as the one included in our paper (1).
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New Oral Anticoagulants:
Good but Not Good Enough!
In the recent article by the European Society of Cardiology
Working Group on anticoagulants in heart disease (1), the authors
describe in great clarity the emerging data regarding new antico-
agulants for the treatment of nonvalvular atrial fibrillation. In the
closing segment of conclusions and implications, the authors list
their concerns regarding “scientific knowledge gaps” and the lack
of clinical tools (like reversal agents or pharmacodynamic moni-
toring objectives and means). Regrettably, in the name of simplic-
ity (i.e., no pharmacodynamic monitoring or dose adjustment and
rigid dose regimens with a one-size-fits-all strategy), we have
taken potentially great drugs and made them good, but truly not
good enough for some of our individual patients.
Why should we bother with pharmacodynamic studies of these
agents? Numerous known factors (body weight, age, renal func-
tion, liver function, Cyp 3A4, and P-glycoprotein inhibitors and
inducers) and probably many unknown factors interact with these
agents to create heterogeneous effect on plasma levels and coagu-
lation profile. Because these agents are meant to be lifelong
prescriptions, they probably command the effort of knowing how
the individual patient responds to the prescribed agent and dose.
This is especially true because we have the option of prescribing
alternative drugs and doses to suit the individual patient best.
Major bleeding is the most common complication of these
agents in patients with nonvalvular atrial fibrillation (exceeding in
most current studies the rate of clinical thromboembolism) and
probably can be reduced by individualized drug prescribing and
dosing based on individual pharmacokinetic and pharmacody-
namic studies. Further, thromboembolism and stroke possibly
related to therapeutic failure potentially can be reduced by moni-
toring and dose adjustments to enhance efficacy.Should we decide to extend the use of these agents to other
patient subsets (valvular atrial fibrillation, mechanical valves, hy-
percoagulable states), establishing monitoring protocols and delin-
eating the therapeutic targets may facilitate the design of future
clinical trials and may optimize both efficacy and safety. As an
example, in the PETRO (Prevention of Embolic and ThROm-
botic events study) among patients receiving dabigatran 150 mg
twice daily, there was an approximately 7-fold difference in
between the fifth and 95th percentile in both peak (95% confidence
interval: 64 to 443 ng/ml) and trough (95% confidence interval: 31
to 225 ng/ml) plasma levels (2). This 7-fold difference translates
into significantly higher exposure, thrombin time, and bleeding
risk. On the other end of the spectrum, approximately 15% of the
patients had peak activated partial thromboplastin time of 40 s.
Future research should attempt to delineate: 1) the best phar-
macodynamic monitoring tools for dabigatran (2) and Xa inhibi-
tors (3,4); 2) the best monitoring protocol (5) (including timing
relative to dosing and frequency); and 3) the best therapeutic
targets. It is very likely that by using these strategies, we could
enhance further the efficacy and safety of these agents and could
extend their use to new indications.
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Reply
We thank Dr. Kaluski and colleagues for their thoughts on the
possibility of individualizing dosing strategies for the new oral
anticoagulants. From a theoretical perspective, the one-size-
fits-all strategy seems not to be ideal, because of the potential
pharmacokinetic interactions, the variability in drug metabo-
lism during lifelong administration, and the inherent risks of
thrombosis in the case of underdosing or of bleeding in the case
of overdosing. For this reason, we favored the European
